Januvia® (Sitagliptin Phosphate) Tablets contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Sitagliptin Phosphate or Januvia improve glycemic control as a monotherapy or in combination with metformin or a PPAR? agonist. Januvia works by increasing levels of natural hormones called incretins. Incretins help to control blood sugar and increase insulin release, especially after a meal. They also decrease the amount of sugar your liver makes.
In monotherapy, Januvia (Sitagliptin Phosphate) is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus and in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPAR? agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
The recommended dose of Januvia (Sitagliptin Phosphate) is 100 mg once daily as monotherapy or as combination therapy with metformin or a PPAR? agonist (e.g., thiazolidinediones). Januvia (Sitagliptin Phosphate) can be taken with or without food. Patients with renal insufficiency may require dosage adjustments.
Common side effects of Januvia (Sitagliptin Phosphate) are headache, nausea, nose/throat infection, or sore throat. If any of these effects persist or worsen, contact your doctor or pharmacist immediately. Severe allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction: rash, itching, skin blisters/peeling, swelling (especially of the face, lips, tongue, or throat), severe dizziness, trouble breathing.
Patients receiving digoxin should be monitored appropriately. Inform your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of digoxin, other diabetes medications such as sulfonylureas (e.g., chlorpropamide, glipizide, glyburide, tolazamide).
Seek immediate medical help if overdose is suspected.
History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.
Januvia (Sitagliptin Phosphate) should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Januvia (Sitagliptin Phosphate) has not been studied in combination with insulin. Before using this medication, tell your doctor or pharmacist your medical history, especially of kidney disease. Limit alcohol while taking this medication because it can increase your risk of developing low blood sugar.